Bio-Gene Technology (ASX:BGT) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Bio-Gene Technology EBITDA Margin %?

Bio-Gene Technology ASX:BGT EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Bio-Gene Technology ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bio-Gene Technology's EBITDA for the six months ended in Dec. 2025 was A$-1.85 Mil. Bio-Gene Technology's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Bio-Gene Technology's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Bio-Gene Technology  (ASX:BGT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bio-Gene Technology EBITDA Margin % Related Terms

Bio-Gene Technology EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology EBITDA Margin % Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial -420.77 -332.95 -527.23 0.00 0.00

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8,621.05 0.00 0.00 0.00 0.00

ASX:BGT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Bio-Gene Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's EBITDA Margin % falls into.


Bio-Gene Technology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bio-Gene Technology's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.067/0
= %

Bio-Gene Technology's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-1.846/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Bio-Gene Technology (ASX:BGT) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Gene Technology and its competitors. According to the industry distribution chart, Bio-Gene Technology ranks #999999 out of 945 companies in the Biotechnology industry.
Is Bio-Gene Technology's EBITDA Margin % too high?
Bio-Gene Technology's current EBITDA Margin % is 0.00%. Based on the distribution chart, Bio-Gene Technology ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #999999 out of 945 companies for EBITDA Margin %. This places Bio-Gene Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.